Analyst ratings can significantly influence investor sentiment and stock prices. The downgrade from 'Outperform' to 'Market Perform' by a reputable analyst like Marc Goodman suggests a less optimistic outlook on Amylyx Pharma's stock, potentially leading to a decrease in investor confidence and a short-term negative impact on the stock price.